Antidiabetic effects of 11β-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis

Diabetes, Obesity and Metabolism

Volumn 11, Issue 7, 2009, Pages 688-699

  Lloyd, D J ^a   Helmering, J ^a   Cordover, D ^a   Bowsman, M ^a   Chen, M ^a   Hale, C ^a   Fordstrom, P ^a   Zhou, M ^a   Wang, M ^a   Kaufman, S A ^a   Veniant M M ^a  

^a AMGEN INC   (United States)

Author keywords

Cortisol; Hypercholesterolemia; Insulin resistance; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; COMPOUND 2922; CYTOKINE; ENZYME INHIBITOR; GLUCOSE; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC MODEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; ANIMAL; BLOOD; BODY COMPOSITION; DISEASE MODEL; DRUG ANTAGONISM; METABOLIC SYNDROME X; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; SIMVASTATIN; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 70449473618     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01034.x     Document Type: Article

References (43)

1. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
2. Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
3. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006, 5:295-309.
4. Wamil M, Seckl JR. Inhibition of 11ss-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007, 12:504-520.
5. Rask E, Olsson T, Soderberg S. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001, 86:1418-1421.
6. Livingstone DE, Jones GC, Smith K. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000, 141:560-563.
7. Wolf G. Glucocorticoids in adipocytes stimulate visceral obesity. Nutr Rev 2002, 60:148-151.
8. tewart PM, Tomlinson JW. Cortisol, 11 beta-hydroxysteroid dehydrogenase type 1 and central obesity. Trends Endocrinol Metab 2002, 13:94-96.
9. Masuzaki H, Paterson J, Shinyama H. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2166-2170.
10. Morton NM, Paterson JM, Masuzaki H. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53:931-938.
11. Wang SJ, Birtles S, de Schoolmeester J. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006, 49:1333-1337.
12. Morton NM, Holmes MC, Fievet C. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001, 276:41293-41300.
13. Berthiaume M, Laplante M, Festuccia W. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2007, 148:2391-2397.
14. Hermanowski-Vosatka A, Balkovec JM, Cheng K. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005, 202:517-527.
15. Gilmour JS, Coutinho AE, Cailhier JF. Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 2006, 176:7605-7611.
16. Cai TQ, Wong B, Mundt SS, Thieringer R, Wright SD, Hermanowski-Vosatka A. Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol 2001, 77:117-122.
17. Thieringer R, Le Grand CB, Carbin L. 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 2001, 167:30-35.
18. Hadoke PW, Macdonald L, Logie JJ, Small GR, Dover AR, Walker BR. Intra-vascular glucocorticoid metabolism as a modulator of vascular structure and function. Cell Mol Life Sci 2006, 63:565-578.
19. Brem AS, Bina RB, King TC, Morris DJ. Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31(Pt 2):459-462.
20. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998, 94:557-572.
21. Nuotio-Antar AM, Hachey DL, Hasty AH. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 2007, 293:E1517-E1528.
22. Hale C, Veniant M, Wang Z. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor. Chem Biol Drug Des 2008, 71:36-44.
23. Lloyd DJ, McCormick J, Helmering J. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr. Am J Physiol Endocrinol Metab 2008, 294:E496-E505.
24. Kim KW, Wang Z, Busby J. The role of tyrosine 177 in human 11beta-hydroxysteroid dehydrogenase type 1 in substrate and inhibitor binding: an unlikely hydrogen bond donor for the substrate. Biochim Biophys Acta 2006, 1764:824-830.
25. Veniant MM, Hale C, Komorowski R. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes Metab 2009, 11:109-17.
26. Lee S, Muniyappa R, Yan X. Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 2008, 294:E261-E270.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
28. Berger J, Tanen M, Elbrecht A. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001, 276:12629-12635.
29. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y. PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 2003, 52:291-299.
30. Mai K, Andres J, Bobbert T. Rosiglitazone decreases 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 2007, 67:419-425.
31. De Sousa Peixoto RA, Turban S, Battle JH, Chapman KE, Seckl JR, Morton NM. Preadipocyte 11{beta}-hydroxysteroid dehydrogenase type 1 is a keto-reductase and contributes to diet-induced visceral obesity in vivo. Endocrinology 2008, 149:1861-8.
32. Liu Y, Park F, Pietrusz JL. Suppression of 11{beta}-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis. Physiol Genomics 2008, 32:343-351.
33. Jellinck PH, Monder C, McEwen BS, Sakai RR. Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. J Steroid Biochem Mol Biol 1993, 46:209-213.
34. Livingstone DE, Walker BR. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 2003, 305:167-172.
35. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005, 54:872-879.
36. Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem 2008, 8:702-710.
37. Alberts P, Nilsson C, Selen G. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144:4755-4762.
38. Berthiaume M, Laplante M, Festuccia WT. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 2007, 293:E1045-E1052.
39. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:285-291.
40. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106:523-531.
41. Duez H, Lamarche B, Uffelman KD. Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab 2008, 93:1722-1729.
42. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006, 37:1923-1932.
43. Chapman KE, Gilmour JS, Coutinho AE, Savill JS, Seckl JR. 11Beta-hydroxysteroid dehydrogenase type 1-a role in inflammation?. Mol Cell Endocrinol 2006, 248:3-8.